Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
8.07
-0.69 (-7.88%)
At close: Oct 31, 2025, 4:00 PM EDT
7.84
-0.23 (-2.85%)
After-hours: Oct 31, 2025, 7:32 PM EDT
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Bicycle Therapeutics stock have a consensus rating of "Buy" and an average price target of $20.73, which forecasts a 156.88% increase in the stock price over the next year. The lowest target is $10 and the highest is $44.
Price Target: $20.73 (+156.88%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 6 | 7 | 7 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $10 → $12 | Buy | Maintains | $10 → $12 | +48.70% | Oct 31, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $27 → $11 | Buy → Hold | Downgrades | $27 → $11 | +36.31% | Oct 31, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $22 → $10 | Buy | Maintains | $22 → $10 | +23.92% | Aug 12, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $13 | Hold | Maintains | $17 → $13 | +61.09% | Aug 12, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $48 → $44 | Buy | Maintains | $48 → $44 | +445.23% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
28.87M
from 35.28M
Decreased by -18.17%
Revenue Next Year
28.86M
from 28.87M
Decreased by -0.03%
EPS This Year
-4.27
from -2.90
EPS Next Year
-4.36
from -4.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.0M | 54.1M | |||
| Avg | 28.9M | 28.9M | |||
| Low | 12.6M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.7% | 87.3% | |||
| Avg | -18.2% | -0.0% | |||
| Low | -64.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.66 | -2.63 | |||
| Avg | -4.27 | -4.36 | |||
| Low | -4.80 | -6.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.